D
Dejian Lai
Researcher at University of Texas Health Science Center at Houston
Publications - 174
Citations - 7047
Dejian Lai is an academic researcher from University of Texas Health Science Center at Houston. The author has contributed to research in topics: Population & Fractional Brownian motion. The author has an hindex of 39, co-authored 167 publications receiving 6409 citations. Previous affiliations of Dejian Lai include Jiangxi University of Finance and Economics & Chinese Academy of Sciences.
Papers
More filters
Journal ArticleDOI
Overweight, Ethnicity, and the Prevalence of Hypertension in School-Aged Children
TL;DR: These results confirm an evolving epidemic of cardiovascular risk in youth, as evidenced by an increase in the prevalence of overweight and hypertension, notably among ethnic minority children.
Journal ArticleDOI
Prognostic value of fractional flow reserve: linking physiologic severity to clinical outcomes.
Nils P. Johnson,Gabor G. Toth,Dejian Lai,Hongjian Zhu,Göksel Açar,Pierfrancesco Agostoni,Yolande Appelman,Fatih Arslan,Emanuele Barbato,Shao-Liang Chen,Luigi Di Serafino,Antonio J. Domínguez-Franco,Patrick Dupouy,Ali Metin Esen,Ozlem Esen,Michalis Hamilos,Kohichiro Iwasaki,Lisette Okkels Jensen,Manuel F. Jiménez-Navarro,Demosthenes G. Katritsis,Sinan Altan Kocaman,Bon-Kwon Koo,Ramón López-Palop,Jeffrey D. Lorin,Louis H. Miller,Olivier Muller,Chang Wook Nam,Niels Oud,Etienne Puymirat,Johannes Rieber,Gilles Rioufol,Josep Rodés-Cabau,Steven P. Sedlis,Yasuchika Takeishi,Pim A.L. Tonino,Eric Van Belle,Edoardo Verna,Gerald S. Werner,William F. Fearon,Nico H.J. Pijls,Bernard De Bruyne,K. Lance Gould +41 more
TL;DR: FFR demonstrates a continuous and independent relationship with subsequent outcomes, modulated by medical therapy versus revascularization, such that lower FFR values confer a higher risk and therefore receive larger absolute benefits fromRevascularization.
Journal ArticleDOI
Effect of Transendocardial Delivery of Autologous Bone Marrow Mononuclear Cells on Functional Capacity, Left Ventricular Function, and Perfusion in Chronic Heart Failure: The FOCUS-CCTRN Trial
Emerson C. Perin,James T. Willerson,Carl J. Pepine,Timothy D. Henry,Stephen G. Ellis,David Zhao,Guilherme V. Silva,Dejian Lai,James D. Thomas,Marvin W. Kronenberg,A. Daniel Martin,R. David Anderson,Jay H. Traverse,Marc S. Penn,Saif Anwaruddin,Antonis K. Hatzopoulos,Adrian P. Gee,Doris A. Taylor,Christopher R. Cogle,Deirdre Smith,Lynette Westbrook,James Chen,Eileen M. Handberg,Rachel E. Olson,Carrie Geither,Sherry Bowman,Judy Francescon,Sarah Baraniuk,Linda B. Piller,Lara M. Simpson,Catalin Loghin,David Aguilar,Sara Richman,Claudia Zierold,Judy Bettencourt,Shelly L. Sayre,Rachel W. Vojvodic,Sonia I. Skarlatos,David Gordon,Ray F. Ebert,Minjung Kwak,Lemuel A. Moyé,Robert D. Simari +42 more
TL;DR: Among patients with chronic ischemic heart failure, transendocardial injection of autologous BMCs compared with placebo did not improve LVESV, maximal oxygen consumption, or reversibility on SPECT.
Journal ArticleDOI
Resistance exercise as a countermeasure to disuse-induced bone loss
Linda Shackelford,Adrian LeBlanc,Adrian LeBlanc,T. B. Driscoll,Harlan J. Evans,Nahid J Rianon,S. M. Smith,Elisabeth Spector,Daniel L. Feeback,Dejian Lai +9 more
TL;DR: The results indicate that resistance exercise had a positive treatment effect and thus might be useful as a countermeasure to prevent the deleterious skeletal changes associated with long-duration spaceflight.
Journal ArticleDOI
Effect of the Use and Timing of Bone Marrow Mononuclear Cell Delivery on Left Ventricular Function After Acute Myocardial Infarction: The TIME Randomized Trial
Jay H. Traverse,Timothy D. Henry,Carl J. Pepine,James T. Willerson,David Zhao,Stephen G. Ellis,John R. Forder,R. David Anderson,Antonis K. Hatzopoulos,Marc S. Penn,Emerson C. Perin,Jeffrey W. Chambers,Kenneth W. Baran,Ganesh Raveendran,Charles R. Lambert,Amir Lerman,Daniel I. Simon,Douglas E. Vaughan,Dejian Lai,Adrian P. Gee,Doris A. Taylor,Christopher R. Cogle,James D. Thomas,Rachel E. Olson,Sherry Bowman,Judy Francescon,Carrie Geither,Eileen M. Handberg,Casey Kappenman,Lynette Westbrook,Linda B. Piller,Lara M. Simpson,Sarah Baraniuk,Catalin Loghin,David Aguilar,Sara Richman,Claudia Zierold,Daniel B. Spoon,Judy Bettencourt,Shelly L. Sayre,Rachel W. Vojvodic,Sonia I. Skarlatos,David Gordon,Ray F. Ebert,Minjung Kwak,Lemuel A. Moyé,Robert D. Simari +46 more
TL;DR: Among patients with STEMI treated with primary PCI, the administration of intracoronary BMCs at either 3 days or 7 days after the event had no significant effect on recovery of global or regional left ventricular function compared with placebo.